Compare Linde PLC (LIN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Novartis AG — how do they compare? Linde PLC trades at $512 (market cap $236.74B), while Novartis AG trades at $156 (market cap $290.25B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| LIN | NVS | |
|---|---|---|
Market Cap | $236.74B | $290.25B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $168.62 |
52-Week Low | $389.38 | $113.50 |
Enterprise Value | $259.10B | $330.27B |
Dividend Yield | 1.25% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $512.05, down 0.2% on the day, with strong fundamentals including 20.44% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with revenue growth to $34.0B in 2025. Recent Q1 2026 results showed EPS of $4.33 beating estimates, while analyst consensus remains strongly bullish with 89% buy ratings and a $564.80 price target.
LIN presents a compelling long-term investment with premium valuation metrics offset by exceptional profitability and dividend growth. Key risks include elevated debt levels (debt-to-asset ratio rising to 31.63% in 2025) and potential margin pressure from economic cycles. The current technical weakness may offer entry points for investors seeking quality industrial exposure with sustainable growth prospects.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
